Breast cancer

Tadashi Ikeda; Hiromitsu Jinno; Akira Matsui; Yoko Mitsui; Sota Asaga; Takeshi Muto; Masahiro Wada; Masaki Kitajima

Breast cancer

Tadashi Ikeda, Hiromitsu Jinno, Akira Matsui, Yoko Mitsui, Sota Asaga, Takeshi Muto, Masahiro Wada, Masaki Kitajima

Research output: Contribution to journal › Review article › peer-review

Abstract

Adjuvant chemo-endocrine therapy for breast cancer (ACETBC) trial has been the first large scaled clinical trial performed in Japan. Several prospective randomized trials have been performed in Japan since ACETBC-1 trial started in 1985. The effect of oral 5-FU agents had been tested in prospective randomized trials and the statistically marginal effect of oral 5-FU agents in adjuvant settings has been reported. Several trials having CMF as a control arm started in 1996 when CMF combination chemotherapy was approved by the government. The results of these trials have not been published. To perform good clinical trials, it is imperative to construct infrastructures including clinical research coordinator, and abolish governmental regulation of the dose of anticancer agents.

Original language	English
Pages (from-to)	1509-1515
Number of pages	7
Journal	Gan to kagaku ryoho. Cancer & chemotherapy
Volume	29
Issue number	9
Publication status	Published - 2002 Sept
Externally published	Yes

ASJC Scopus subject areas

Medicine(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{945858f76a6a48ee8e6be909ad301ae1,

title = "Breast cancer",

abstract = "Adjuvant chemo-endocrine therapy for breast cancer (ACETBC) trial has been the first large scaled clinical trial performed in Japan. Several prospective randomized trials have been performed in Japan since ACETBC-1 trial started in 1985. The effect of oral 5-FU agents had been tested in prospective randomized trials and the statistically marginal effect of oral 5-FU agents in adjuvant settings has been reported. Several trials having CMF as a control arm started in 1996 when CMF combination chemotherapy was approved by the government. The results of these trials have not been published. To perform good clinical trials, it is imperative to construct infrastructures including clinical research coordinator, and abolish governmental regulation of the dose of anticancer agents.",

author = "Tadashi Ikeda and Hiromitsu Jinno and Akira Matsui and Yoko Mitsui and Sota Asaga and Takeshi Muto and Masahiro Wada and Masaki Kitajima",

year = "2002",

month = sep,

language = "English",

volume = "29",

pages = "1509--1515",

journal = "Japanese Journal of Cancer and Chemotherapy",

issn = "0385-0684",

publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

number = "9",

}

TY - JOUR

T1 - Breast cancer

AU - Ikeda, Tadashi

AU - Jinno, Hiromitsu

AU - Matsui, Akira

AU - Mitsui, Yoko

AU - Asaga, Sota

AU - Muto, Takeshi

AU - Wada, Masahiro

AU - Kitajima, Masaki

PY - 2002/9

Y1 - 2002/9

N2 - Adjuvant chemo-endocrine therapy for breast cancer (ACETBC) trial has been the first large scaled clinical trial performed in Japan. Several prospective randomized trials have been performed in Japan since ACETBC-1 trial started in 1985. The effect of oral 5-FU agents had been tested in prospective randomized trials and the statistically marginal effect of oral 5-FU agents in adjuvant settings has been reported. Several trials having CMF as a control arm started in 1996 when CMF combination chemotherapy was approved by the government. The results of these trials have not been published. To perform good clinical trials, it is imperative to construct infrastructures including clinical research coordinator, and abolish governmental regulation of the dose of anticancer agents.

AB - Adjuvant chemo-endocrine therapy for breast cancer (ACETBC) trial has been the first large scaled clinical trial performed in Japan. Several prospective randomized trials have been performed in Japan since ACETBC-1 trial started in 1985. The effect of oral 5-FU agents had been tested in prospective randomized trials and the statistically marginal effect of oral 5-FU agents in adjuvant settings has been reported. Several trials having CMF as a control arm started in 1996 when CMF combination chemotherapy was approved by the government. The results of these trials have not been published. To perform good clinical trials, it is imperative to construct infrastructures including clinical research coordinator, and abolish governmental regulation of the dose of anticancer agents.

UR - http://www.scopus.com/inward/record.url?scp=0036728663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036728663&partnerID=8YFLogxK

M3 - Review article

C2 - 12355936

AN - SCOPUS:0036728663

SN - 0385-0684

VL - 29

SP - 1509

EP - 1515

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

IS - 9

ER -

Breast cancer

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this